GYRE THERAPEUTICS, INC. (GYRE)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 15M 30M 45M Q2 '13: 0 Q3 '13: 0 Q4 '13: 93K Q1 '14: 87K Q2 '14: 36K Q3 '14: 25K Q4 '14: 127K Q1 '15: 60K Q2 '15: 0 Q1 '17: 271K Q2 '17: 111K Q3 '17: 318K Q4 '17: 318K Q1 '18: 6K Q2 '18: 0 Q3 '18: 0 Q4 '18: 0 Q1 '20: 16.4M Q2 '20: 1.7M Q3 '20: 893K Q4 '20: 2M Q1 '21: 1.5M Q2 '21: 1.1M Q3 '21: 2.3M Q4 '21: 2.4M Q1 '22: 794K Q1 '23: 24.9M Q2 '23: 29.3M Q3 '23: 32M Q4 '23: 27.1M Q1 '24: 27.2M Q2 '24: 25.2M Q3 '24: 25.5M Q4 '24: 27.9M Q1 '25: 22.1M Q2 '25: 29.7M Q3 '25: 30.6M Q4 '25: 37.2M Q1 '26: 22.5M Q2 '26: 29.1M Q2 '14 Q1 '17 Q2 '18 Q3 '20 Q4 '21 Q4 '23 Q1 '25 Q2 '26

Gross Profit Quarterly

0 15M 30M 45M Q1 '23: 23.8M Q2 '23: 28.3M Q3 '23: 30.9M Q4 '23: 25.9M Q1 '24: 26.2M Q2 '24: 24.5M Q3 '24: 24.5M Q4 '24: 26.7M Q1 '25: 21.2M Q2 '25: 25.6M Q3 '25: 28.9M Q1 '23 Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25

Operating Income Quarterly

-105M -70M -35M 0 35M 70M 105M Q3 '16: -5.7M Q4 '16: -5.2M Q1 '17: -4.2M Q2 '17: -5.9M Q3 '17: -5.9M Q4 '17: -5.8M Q1 '18: -6.7M Q2 '18: -7.1M Q3 '18: -8.3M Q4 '18: -11.7M Q1 '19: -15.7M Q2 '19: -14.4M Q3 '19: -13.2M Q4 '19: -14M Q1 '20: -5.1M Q2 '20: -17.4M Q3 '20: -16.1M Q4 '20: -18.8M Q1 '21: -22.4M Q2 '21: -19.9M Q3 '21: -25.2M Q4 '21: -20.3M Q1 '22: -14.7M Q2 '22: 51.5M Q3 '22: -5.2M Q4 '22: -22.5M Q1 '23: 6.7M Q2 '23: 5M Q3 '23: 12.8M Q4 '23: -91.6M Q1 '24: 8.1M Q2 '24: 3.2M Q3 '24: 4.2M Q4 '24: 665K Q1 '25: 2.3M Q2 '25: -2.2M Q3 '25: 6.9M Q4 '25: 118K Q1 '26: -9.4M Q2 '26: -14.4M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Net Income Quarterly

-90M -60M -30M 0 30M 60M 90M Q3 '16: -4.8M Q4 '16: -3.8M Q1 '17: -4.1M Q2 '17: -5.9M Q3 '17: -5.8M Q4 '17: -5.8M Q1 '18: -5M Q2 '18: -6.5M Q3 '18: -7.7M Q4 '18: -10.8M Q1 '19: -15.1M Q2 '19: -13.8M Q3 '19: -12.7M Q4 '19: -13.6M Q1 '20: -4.1M Q2 '20: -17.2M Q3 '20: -16M Q4 '20: -18.9M Q1 '21: -22.4M Q2 '21: -19.9M Q3 '21: -25.2M Q4 '21: -20.3M Q1 '22: -14.5M Q2 '22: 51.6M Q3 '22: -4.9M Q4 '22: -27.9M Q1 '23: 4.2M Q2 '23: 3.8M Q3 '23: 7.5M Q4 '23: -81.7M Q1 '24: 9.9M Q2 '24: 4.5M Q3 '24: 2.9M Q4 '24: 598K Q1 '25: 4.9M Q2 '25: -2.2M Q3 '25: 5.9M Q4 '25: 1.2M Q1 '26: -18.6M Q2 '26: -14.3M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Cost of Revenue Quarterly

0 800K 1.6M 2.4M Q1 '23: 1.1M Q2 '23: 1.1M Q3 '23: 1.2M Q4 '23: 1.2M Q1 '24: 979K Q2 '24: 770K Q3 '24: 958K Q4 '24: 1.2M Q1 '25: 894K Q2 '25: 1.2M Q3 '25: 1.6M Q4 '25: 1.7M Q1 '26: 1.2M Q2 '26: 2.2M Q2 '23 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

Operating Cash Flow Quarterly

-30M -15M 0 15M 30M 45M Q3 '16: -5.1M Q4 '16: -5M Q1 '17: -4.3M Q2 '17: -4.4M Q3 '17: -4.9M Q4 '17: -6.3M Q1 '18: -5.1M Q2 '18: -7.4M Q3 '18: -7M Q4 '18: -9M Q1 '19: -15M Q2 '19: -11.5M Q3 '19: -9.1M Q4 '19: -8.1M Q1 '20: -4.8M Q2 '20: -15.1M Q3 '20: -13M Q4 '20: -22.1M Q1 '21: -24.4M Q2 '21: -20.1M Q3 '21: -21.6M Q4 '21: -17.7M Q1 '22: -12.1M Q2 '22: -12.3M Q3 '22: -7.3M Q4 '22: 42.3M Q1 '23: 10.4M Q2 '23: 4.5M Q3 '23: 7.6M Q4 '23: 3.4M Q1 '24: 2.9M Q2 '24: -5.5M Q3 '24: 1.7M Q4 '24: -2.8M Q1 '25: -129K Q2 '25: -7.5M Q3 '25: 14.2M Q4 '25: -5.6M Q1 '26: 3.2M Q2 '26: -16.7M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Free Cash Flow Quarterly

-24M -16M -8M 0 8M 16M 24M Q2 '13: -10.4M Q3 '13: -9.7M Q4 '13: -11.2M Q4 '14: 18M Q4 '15: -5.2M Q1 '16: -4.8M Q2 '16: -3.9M Q3 '16: -5.1M Q4 '16: -5.1M Q1 '17: -4.3M Q2 '17: -4.4M Q3 '17: -4.9M Q4 '17: -6.3M Q1 '18: -5.3M Q2 '18: -7.4M Q3 '18: -7M Q4 '18: -9.2M Q1 '19: -15M Q2 '19: -11.5M Q3 '19: -9.1M Q4 '19: -8.1M Q1 '20: -4.8M Q2 '20: -15.2M Q3 '20: -13.2M Q3 '21: -22.1M Q4 '21: -17.7M Q1 '23: 8.7M Q2 '23: 2.1M Q3 '23: 5.6M Q4 '23: 1M Q1 '24: 2.7M Q2 '24: -6.9M Q3 '24: 1M Q4 '24: -2.8M Q1 '25: -251K Q2 '25: -7.8M Q3 '25: 13.6M Q4 '25: -5.8M Q1 '26: 3M Q2 '26: -17M Q4 '15 Q1 '17 Q2 '18 Q3 '19 Q3 '21 Q4 '23 Q1 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 40M 80M 120M Q2 '10: 30.2M Q3 '10: 30.2M Q1 '11: 30.4M Q2 '11: 30.7M Q3 '11: 33.4M Q4 '11: 33.4M Q1 '12: 33.8M Q2 '12: 33.6M Q3 '12: 33.5M Q4 '12: 33.6M Q1 '13: 33.6M Q2 '13: 33.6M Q3 '13: 33.6M Q2 '21: 31.3M Q3 '21: 31.4M Q1 '22: 31.5M Q2 '22: 31.5M Q3 '22: 31.5M Q1 '23: 78.9M Q2 '23: 78.9M Q3 '23: 78.9M Q1 '24: 102.6M Q2 '24: 102.2M Q3 '24: 102.6M Q1 '25: 102M Q2 '25: 89.2M Q3 '25: 104M Q1 '26: 91.3M Q2 '26: 100.6M Q2 '10 Q3 '11 Q3 '12 Q3 '13 Q2 '22 Q3 '23 Q1 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-24.00 -16.00 -8.00 0.00 8.00 16.00 24.00 Q2 '15: -19.86 Q3 '15: -16.71 Q4 '15: -13.65 Q1 '16: -10.69 Q2 '16: -12.42 Q3 '16: -17.53 Q4 '16: -21.73 Q1 '17: -21.59 Q2 '17: -17.79 Q3 '17: -13.09 Q4 '17: -9.40 Q1 '18: -5.39 Q2 '18: -3.40 Q3 '18: -2.70 Q4 '18: -2.67 Q1 '19: -3.37 Q2 '19: -3.98 Q3 '19: -4.40 Q4 '19: -4.60 Q1 '20: -3.62 Q2 '20: -3.43 Q3 '20: -3.10 Q4 '20: -2.85 Q1 '21: -3.36 Q2 '21: -3.04 Q3 '21: -3.11 Q4 '21: -2.87 Q1 '22: -2.54 Q2 '22: -0.26 Q3 '22: 0.38 Q4 '22: 0.03 Q1 '23: 0.52 Q2 '23: -1.10 Q3 '23: -0.89 Q4 '23: -1.41 Q2 '25: -0.02 Q3 '25: 0.00 Q4 '25: 0.02 Q1 '26: -0.08 Q2 '26: -0.17 Q2 '16 Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.